Objective To retrospectively evaluate the risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) and stent dysfunction after performing preoperative biliary drainage (BD) in patients with malignant biliary stricture. Methods Between January 2003 and February 2013, 105 consecutive patients who had undergone transpapillary BD before surgery were enrolled in this study. Procedure-related complications, stent dysfunction rates, and their respective risk factors were investigated. PEP was defined according to the consensus guidelines. Results Fifty-five patients had bile duct cancer, 31 had pancreatic cancer, 16 had ampullary cancer, and 3 had gallbladder cancer. Endoscopic biliary stenting (EBS) and nasobiliary drainage (NBD) were performed in 84 patients and 21 patients, respectively. PEP occurred in 10% of the patients, with a significantly higher frequency in those with hilar/upper bile duct stricture (p=0.026) and a normal bilirubin level at admission (p= 0.016). Of the 84 patients who underwent initial EBS, stent dysfunction occurred in 13%. The mean number of days from EBS to stent dysfunction was 14±12 days. A multivariate analysis revealed a male gender (p= 0.048), a stent diameter ! 8 Fr (p=0.036), and an ERCP procedure time " 45 minutes (p=0.021) to be risk factors for stent dysfunction. No NBD tube dysfunction was observed. Conclusion Patients with upper/hilar bile duct stricture or a normal bilirubin level are at high risk of developing PEP after preoperative BD. NBD or EBS with a large-bore stent is therefore recommended as preoperative BD.
Introduction
creased the perioperative complication rates in patients with pancreatic cancer who underwent pancreatoduodenectomy. The reported perioperative complications were related mainly to post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) and biliary stent dysfunction. There are few published reports regarding the risk factors for PEP and biliary stent dysfunction associated with preoperative transpapillary BD. We therefore retrospectively evaluated the risk factors for PEP and stent dysfunction after preoperative BD.
Materials and Methods

Study population
From January 2003 to February 2013, 355 patients (pancreatic cancer, 135; bile duct cancer, 87; gallbladder cancer, 84; ampullary cancer, 49) underwent curative surgery at Sendai City Medical Center. Of these, 105 consecutive patients (mean age, 70 years; including 68 males and 37 females) who had undergone transpapillary BD before surgery were included in this retrospective study. The patients excluded from this study were those who underwent EUS-BD (n=6) or PTBD (n=4), those who had undergone biliary drainage at another hospital (n=3), those who underwent biliary drainage during a second or third ERCP rather than during initial ERCP (n=3), those who received neoadjuvant chemotherapy (n=3), and those whose records regarding biliary drainage were inadequate (n=1). Data from the patient records and the institution's endoscopy database were analyzed.
Several imaging modalities, such as extracorporeal ultrasound (US), computed tomography (CT), magnetic resonance cholangiography (MRCP), EUS, ERCP, and intraductal ultrasonography (IDUS) were performed in order to make a diagnosis and to determine the resectability of the tumor. Transpapillary BD (EBS or NBD) was first attempted during ERCP. Pathological examinations, such as bile/pancreatic duct biopsy or bile/pancreatic juice cytology were also performed as necessary. The selection of the transpapillary BD method (EBS or NBD) was made at the discretion of each endoscopist.
Biliary drainage procedures
ERCP-related procedures were carried out in a standard fashion by using a side-viewing duodenoscope (JF230, 240, 260V, TJF230, 240, 260V: Olympus Medical Systems, Tokyo, Japan). Selective biliary cannulation was usually performed by the conventional contrast-assisted cannulation technique using a cannula/sphincterotome. We routinely performed biliary sphincterotomy, except in patients with ampullary cancer or those receiving an antithrombotic agent. The stent used for BD was a 6, 7, or 8 Fr pigtail stent (Gadelius Medical, Tokyo, Japan) or a 7, 8.5, or 10 Fr straight stent (Boston Scientific, Natick, USA). NBD was performed using a 6 Fr pigtail catheter (Gadelius Medical) or a 7.2 Fr pigtail catheter (Hanako Medical, Saitama, Japan). After the drainage procedure, the patients continued fasting for a minimum of 24 hours and received antibiotics for 2 days. Until March 2009, the patients also received a 2-day drip infusion of a prophylactic protease inhibitor (nafamostat mesilate 20 mg/day). Beginning in April 2009, however, this drug was not administered because our data suggested that it did not decrease PEP (5).
Definition of drainage effects and complications
An improvement of jaundice was defined as a decrease in the serum bilirubin level to less than 3 mg/dL or to 1/3 of the level measured at the time of preoperative BD. Early complications were defined as those that occurred 3 days after the first BD, and late complications were defined as those that occurred on or after the third day. In accordance with a consensus guideline (6), PEP was defined as the presence of abdominal symptoms (e.g., abdominal pain and nausea) and physical findings (e.g., abdominal tenderness) within 24 hours after the procedure, and an increase in the serum amylase level greater than three times the upper normal limit. The severity of PEP was categorized into three groups: mild, a prolongation of planned hospitalization by 1-3 days; moderate, hospitalization lasting 4-10 days; severe, hospitalization for more than 10 days or cases of hemorrhagic pancreatitis, phlegmon, or pseudocyst. The severity of cholangitis was defined based on the Tokyo Guidelines 13 (7) . Hemorrhage was defined as the requirement for blood transfusion or for endoscopic hemostasis after the drainage procedure. Stent dysfunction was defined by the presence of various symptoms (e.g., abdominal pain, high fever, and vomiting) and elevated serum hepatobiliary enzyme levels. Postoperative complications such as pancreatic fistula, delayed gastric emptying, and hemorrhage were diagnosed based on the definitions of the International Study Group for Pancreatic Surgery for pancreatoduodenectomy (8) (9) (10) . Postoperative hyperbilirubinemia was defined as a serum bilirubin level greater than 2 mg/dL at 2 weeks after surgery.
Statistical analysis
Data were analyzed for statistical differences using Fisher's exact test. Regarding the risk factors for PEP and stent dysfunction, variables found to be significant according to a univariate analysis were then analyzed by multiple logistic regression. A p value <0.05 was regarded as significant. Statistical analyses were performed with the StatView Ver. 5.0 software program (SAS Institute, Cary, USA). n=5) before BD. Fifty-five patients had bile duct cancer, 31 had pancreatic cancer, 16 had ampullary cancer, and 3 had gallbladder cancer. Biliary stricture at the ampullary or lower/middle bile duct was observed in 87% (n=91) of patients, and 82% (n=86) underwent pancreatoduodenectomy. EBS and NBD were performed in 80% (n=84) and 20% (n= 21) of patients, respectively (Table 2) . EBS was performed in more patients with pancreatic cancer than NBD (34.5% vs. 9.5%, p=0.03), while NBD was used in more patients with bile duct cancer (44.0% vs. 85.7%, p=0.01). All patients with ampullary cancer underwent EBS. Of the 84 patients who underwent initial EBS, the bore diameter of the stent was ! 8 Fr in 61% (n=51). EBS was performed with a single plastic stent in 98% (n=82) of the patients. The mean procedure times for EBS, NBD, and transpapillary BD were 43±15 minutes, 49±11 minutes, and 44±14 minutes, respectively ( Table 2 ). The median number of days from BD to surgery was 27 (range: ). An improvement of jaundice was achieved in 99% (n=101) of all patients. In 92% (n=97) of these patients, the serum bilirubin level decreased to less than 3.0 mg/dL at surgery. In the remaining 4 patients with a decrease in the serum bilirubin level of less than 1/3, the bilirubin level at surgery was 3.1 mg/dL (range: 3.0-3.4 mg/dL). The serum bilirubin level in patients who demonstrated an improvement of jaundice at surgery was 1.5 mg/dL (range: 0.4-7.6 mg/dL). The serum bilirubin level of 4 patients (EBS, 2; NBD, 2) without any improvement of jaundice was 5.6 mg/dL (range: 4.0-7.6 mg/dL); these individuals underwent surgery without any adverse events.
Results
Improvement of jaundice
Complications and risk factors for post-ERCP pancreatitis and stent dysfunction
Of the 105 patients who underwent ERCP, PEP developed in 10% (n=10) (mild: 6, moderate: 4) ( Table 3) . Periampullary perforation occurred in one patient during precut sphincterotomy. Both conditions improved with conservative therapy. In the cases of transpapillary BD, the frequency of PEP in patients with hilar/upper bile duct stricture was significantly higher than in those with lower/middle bile duct stricture (40% vs. 10%, p=0.027). A multivariate analysis revealed hilar/upper bile duct stricture and a normal bilirubin level at admission to be risk factors for PEP (p=0.026, odds ratio (OR) 7.44, 95% confidence interval (CI) 1.27-43.6; p= 0.016, OR 10.3, 95% CI 1.55-68.5, respectively) ( Table 4) . The previously reported risk factors for PEP, e.g., female gender, precutting, and long ERCP procedure time due to difficult cannulation, were not found to be significant. In addition, the stent size did not affect the onset of PEP, while biliary sphincterotomy was performed in 80% of patients (n=84). No patients who had undergone prophylactic pancreatic duct stenting (n=12) developed PEP.
The clinical course of the patients who underwent preoperative biliary drainage at our institution is shown in Figure. Late complications were observed in 20% (n=21) of the patients after BD. Of the 99 patients (EBS: n=84, NBD: n=15) who underwent EBS during the preoperative period, stent dysfunction was observed in 16% (n=16) before surgery ( Table 5 ). The dislodgment of the drainage tube occurred in 3 patients (EBS: 2, NBD: 1). Post-ERCP bleeding occurred in 2 patients after biliary sphincterotomy, and 2 patients developed acute cholecystitis 7 and 17 days after BD, respectively. In the 84 patients who underwent initial EBS, 56% (n=47) underwent surgery without stent exchange (Figure) . In 30% (n=25) of these 84 patients, the stent was exchanged due to a re-estimation of the tumor staging by bile cytology, bile duct biopsy, and/or cholangioscopy. Stent dysfunction after the initial EBS was observed in 13% (n= 11) of all patients; they underwent an exchange of EBS (7%, n=6) or NBD (6%, n=5). The mean number of days from initial EBS placement to stent dysfunction was 14±12 (range: 6-47), while the median number of days from initial EBS to surgery was 27. The stent dysfunction rates were similar regardless of whether the period from initial EBS to surgery was below (n=40) or above (n=44) the median (10% vs. 16%, p=0.423). However, stent exchange for estimating tumor staging was performed less frequently when this duration was below the median (15% vs. 43%, p=0.03). A multivariate analysis revealed a male gender (p=0.048, OR 9.3, 95% CI 1.02, 84.6), a stent diameter ! 8 Fr (p=0.036, OR 10.5, 95% CI 1.16, 95.0), and the procedure time for ERCP " 45 minutes (p=0.021, OR 6.12, 95% CI 1.32, 28.4) to be significant risk factors for stent dysfunction in patients who underwent initial EBS (Table 6 ). The biliary stent shapes, such as straight or pigtail type, were not found to be significant factors. The tube was exchanged in 71% (n=15) of the 21 patients who underwent NBD because of either a reestimation of the tumor staging or patient intolerance, while NBD tube dysfunction was not observed before surgery.
Postoperative complications were seen in 62% (n=65) of the 105 patients (Table 7) . Of the 89 patients who underwent either pancreatoduodenectomy or hepatopancreatoduodenectomy, a pancreatic fistula was observed in 55% (n=49) (Grade A: n=13, Grade B: n=37, Grade C: n=3). Surgical site infection, delayed gastric emptying, and hyperbilirubinemia occurred in 29%, 12%, and 4% of the patients, respectively. These complications were ameliorated with conservative therapy. Of the 5 patients who experienced postoperative hemorrhage, 4 were treated with interventional radiology. One patient underwent additional surgery for abdominal hemorrhage 9 days after hepatectomy because the interventional radiology treatment was unsuccessful. However, this patient died the day after the re-operation. Neither PEP nor 
Discussion
We herein demonstrated that the risk factors for PEP after preoperative BD were upper/hilar bile duct stricture and a normal bilirubin level. In addition, a male gender, a stent diameter ! 8 Fr, and ERCP procedure time " 45 minutes were risk factors for stent dysfunction.
A detailed evaluation of suspected pancreatobiliary cancer is mandatory for making appropriate therapeutic decisions. The diagnosis and staging of these tumors are based on both the imaging and histological findings. Pancreatobiliary cancers are often associated with jaundice due to biliary stricture resulting from tumor invasion. Preoperative imaging evaluations for pancreatobiliary cancer are generally performed using various modalities such as US, CT, EUS, and MRI. ERCP-related procedures, including cholangiography, intraductal ultrasonography, cholangioscopy, and bile duct biopsy, are the most popular procedures for tumor staging and obtaining histopathological samples. EUS-guided fine needle aspiration (EUS-FNA) is a useful technique for pathological evaluation; however, preoperative EUS-FNA was found to be associated with a risk of tumor seeding (11) . In contrast, a biopsy of a biliary stricture and/or cytology of bile or pancreatic juice can be performed at the same time as ERCP without any risk of tumor seeding.
Although the necessity of preoperative BD in patients with malignant biliary stricture remains under discussion (4), cholangiography without BD in patients with a biliary stricture has been reported to be associated with cholangitis (12) . Generally, BD associated with cholangitis is mandatory before surgery. A progression of jaundice is often observed during preoperative examinations. Some authors have reported that preoperative BD reduces the postoperative complication rates (13, 14) . Moreover, the intraoperative hemodynamics are more unstable in patients with obstructive jaundice compared to those without (15) . Therefore, preoperative BD is routinely performed in Japan. Frequent complications associated with preoperative transpapillary BD include PEP and stent dysfunction. However, investigations into the risk factors for such complications have been lacking.
PEP is one of the most important complications associated with ERCP-related procedures. Several risk factors for PEP have been reported, such as sphincter of Oddi dysfunction, a female gender, a history of pancreatitis, and a nondilated bile duct (16) (17) (18) . PEP occurred in 10% of all patients in the present study. This ratio is relatively high compared with other reports; however, no patients suffered from severe PEP. This may be explained by several procedures that were conducted in this study for diagnosing biliary stricture, such as intraductal ultrasonography and a biopsy of the bile duct. PEP occurs more frequently with therapeutic ERCP than with diagnostic ERCP (16, 19) . Moreover, biliary sphincterotomy and biliary stenting have also been reported to increase the frequency of PEP (17, 20, 21) . The risk factors for PEP in this study were hilar/upper bile duct stricture and a normal bilirubin level at admission. The apparent reason why hilar/upper bile duct stricture was a risk factor for PEP is that the devices that passed several times across the papilla of Vater may have increased the papillary burden. The reason for the relationship between a normal bilirubin level and PEP is still unclear, although the former was previously reported to be a risk factor for PEP (22) . We routinely perform transpapillary biopsies of biliary stricture and/or cytology of bile or pancreatic juice for pathological evaluation before conducting BD. Considering the concern about complications after ERCP-related procedures and the diagnostic accuracy of EUS-FNA, preoperative EUS-FNA without BD, especially for pancreatic cancer, may be useful for patients without jaundice.
In the present study, no patients who underwent prophylactic pancreatic duct stenting developed PEP despite their high risk for this condition. This technique was also effective for reducing the incidence of PEP (23, 24) . The prevention of PEP, such as through prophylactic pancreatic duct stenting, should be considered for preoperative BD in patients with either hilar or upper bile duct cancer.
There have been few reports regarding the risk factors for biliary stent dysfunction (25) , particularly concerning dysfunction of plastic stents for preoperative BD. EBS has several advantages, such as physiological internal drainage, minimal pain after the procedure, and easy stent exchange. Therefore, EBS using a plastic stent is currently widely employed for preoperative BD. In the present study, the risk factors for stent dysfunction after EBS were a male gender, a biliary stent diameter ! 8 Fr, and an ERCP procedure time " 45 minutes. Lengthy ERCP-related procedures, i.e., lasting longer than the mean procedure time for transpapillary BD, may increase debris formation in the bile duct. Stents smaller than or equal to 8 Fr tended to be more frequently occluded. Preoperative BD with a self-expanding metal stent has been found to be effective (26) , most likely because the period from BD to surgery tends to be prolonged due to the increasing number of patients who receive neoadjuvant chemotherapy for pancreatic cancer (27) (28) (29) . Although largebore stents are theoretically preferable for preoperative BD, prospective randomized controlled trials comparing plastic and metal stents are necessary.
No obstruction of NBD tubes was observed in this study. Preoperative NBD for patients with hilar cholangiocarcinoma was reported to have a lower complication ratio than EBS or PTBD (30) . NBD has several advantages, such as reliable drainage, a lower incidence of retrograde cholangitis, and an easy diagnostic evaluation of cholangiography or bile cytology. On the other hand, NBD has some disadvantages, such as nasopharyngeal discomfort, impaired activities of daily living, malabsorption of fat-soluble vitamins, and a risk of tube dislodgement. NBD may be therefore suitable for preoperative drainage when these disadvantages are considered to be acceptable.
Our study is associated with some limitations. First, it used a retrospective design and was conducted at a single center. Therefore, the sample size was small. Second, the drainage techniques were not specified prior to the study and were instead chosen at the discretion of the operator. However, this study is thought to provide useful information for the management of patients who undergo surgery after BD. Prospective studies regarding the usefulness and safety of preoperative BD in a larger number of patients are awaited.
In conclusion, preoperative BD was found to be effective with acceptable complication rates. In cases with either upper/hilar bile duct stricture or a normal bilirubin level, endoscopists should be aware of the occurrence of PEP after transpapillary BD. NBD or biliary stenting with a large-bore stent should be considered, especially in patients with longer ERCP procedure times.
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